ZLY-18

N/A

Report date: 2026/01/20 18:01:30

NME

Base Information

Drug NameZLY-18

Drug Alias NameZLY-18

ClassificationSmall molecules

Mechanisms of ActionPeroxisome proliferator-activated receptor α agonistsFree fatty acid receptor 1 agonistsPeroxisome proliferator-activated receptor delta agonists +[4]

TargetsFree fatty acid receptor 1Peroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor delta +[4]

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGuangdong Pharmaceutical University

China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Pharmaceutical University

Inactive CompaniesN/A

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A